News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
|Articles|September 17, 2019

PE 2020 Media Kit

External Link - PE_2020_MediaKit_final_r1.pdf

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion

ByNicholas Saraceno, Editor
December 5th 2025
Stock.adobe.com

FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma

ByNicholas Jacobus
December 5th 2025
© JHVEPhoto - ©  JHVEPhoto - stock.adobe.com

Former FDA Commissioners Warn New Vaccine Policies Could Undermine Longstanding Regulatory Framework

ByAndy Studna
December 4th 2025
Pharmaceutical Executive

Pharmaceutical Executive Daily: FDA Names Tracy Beth Høeg as Acting Director of CDER

ByNicholas Jacobus
December 4th 2025
Stock.adobe.com

FDA Approves Expanded Indication of Jaypirca for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

ByNicholas Jacobus
December 4th 2025

Trending on PharmExec

1

Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion

2

Pharmaceutical Executive Daily: FDA Names Tracy Beth Høeg as Acting Director of CDER

3

FDA Appoints Tracy Beth Høeg as Acting Director of CDER

4

FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma

5

Five Steps for Successful CGT Commercialization Through Health Systems Partnerships

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us